MedTrace Logo

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nascertib Moves Through the Body In Healthy Adult Japanese Participants

NCT07600762 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-22

No results posted yet for this study

Summary

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nascertib Moves Through the Body In Healthy Adult Japanese Participants

Conditions

  • Healthy Volunteer

Interventions

DRUG

Nascertib

Oral tablet

DRUG

Placebo for Nascertib

Oral tablet

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07600762 on ClinicalTrials.gov